New diagnostics tool, the Xpert Ultra assay, improves detection of mycobacterium tuberculosis

August 29, 2017, American Society for Microbiology

Researchers have demonstrated a new, improved version of the Xpert MTB/RIF assay, a test for Rifampicin-resistance (RIF-R). The Xpert "Ultra" assay overcomes the shortcomings of the current Xpert assay to significantly improve tuberculosis detection, especially in patients with pauci-bacillary disease. The new Xpert Ultra assay also provides a more reliable detection of Rifampicin resistance (RIF-R). The research is published this week in mBio, an open-access journal of the American Society for Microbiology.

The Xpert MTB/RIF (Xpert) assay, the first point-of-care assay for tuberculosis (TB), was endorsed by World Health Organization in December 2010. Although it shows high overall sensitivity and specificity, it has several limitations, such as yielding both false positive and false negative results for the prediction of RIF-R in pauci-bacillary samples. This study shows that the new Ultra assay format, which includes new gene target amplifications and improves previously amplified targets, overcomes many of the known shortcomings of the Xpert assay, and should significantly improve TB detection.

Explore further: Automated Ebola blood test performs well in field evaluation

Related Stories

Automated Ebola blood test performs well in field evaluation

March 29, 2016
An automated "sample-to-answer" system could provide Ebola virus disease (EVD) diagnosis more quickly and easily than the current standard test, according to research published this week in PLOS Medicine. In a field evaluation ...

Assay for pulmonary tuberculosis and rifa mpicin resistance in adults

January 22, 2014
A second systematic review of a diagnostic test for tuberculosis (TB) endorsed by the World Health Organisation (WHO), has confirmed the accuracy of the test. The updated review assessing the accuracy of Xpert® MTB/RIF includes ...

FDA approves new test to help detect drug-resistant bacteria

July 1, 2016
(HealthDay)—The Xpert Carba-R Assay diagnostic, which tests patient specimens for genetic markers associated with drug-resistant bacteria, has been approved by the U.S. Food and Drug Administration.

New TB drug-resistance test shows promise but needs investment for those diagnosed to be cured

July 26, 2011
Two research studies in this week's PLoS Medicine suggest that a new automated DNA test for tuberculosis (Xpert MTB/RIF), which can detect TB within 2 hours and has been endorsed by the World Health Organization, can significantly ...

XPert MTB/RIF cost effective for TB diagnosis in low- and middle-income settings

November 8, 2011
A study led by Frank Cobelens of the Amsterdam Institute of Global Health and Development, Amsterdam, The Netherlands and colleagues reports on the cost-effectiveness of implementing the Xpert MTB/RIF diagnostic test for ...

Tuberculosis: WHO-endorsed test offers rapid detection

January 30, 2013
A diagnostic test for tuberculosis (TB) can accurately and quickly detect both TB and drug-resistant strains, according to a new study. The authors of a new systematic review assessing the diagnostic accuracy of the Xpert® ...

Recommended for you

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.